LRRK2 and Parkinson disease: Utilizing iPSC from LRRK2 G2019S PD patients, Sonnien et al. (87) observed increased production of α-synuclein, altered metabolism and calcium homeostasis, increased release of cytokines, increased levels of polyamines and their precursors, and decreased levels of lysophosphatidylethanolamine in the astrocytes of LRRK2 mutation PD patients.